AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Adjusted R&D Expense — Non-GAAP by Quarter
Adjusted R&D Expense — Non-GAAP ($M) ($M)
AbbVie Adjusted R&D Expense — Non-GAAP: $2,314M in Q2 2026, up 9.4% from a year earlier. That is the highest of the 17 quarters on record here.
Latest, Q2 2026
2,314
Period ended Jun 30, 2026
Change on a year earlier
+9.4%
2,115 in Q2 2025
History
17 quarters
Since Q2 2022
Sources
17
Documents cited below
Where the Q2 2026 figure comes from
“|| As adjusted (non-GAAP) | $ | 2,598 | $ | 3,574 | $ | 2,314 | $ | (79)”
Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Reported in Form 8-K Non-GAAP Reconciliations.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). AbbVie Adjusted R&D Expense — Non-GAAP ($M), quarterly Q2 2022–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/rd-adj-exp
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.